A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with gliobl...